Paper33906641
Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review.
Liu C and 2 others. Cancer Cell Int, 2021. Cited by 80 papers, by iCite.
Cite this record
ConductScience Library. Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review. Papers, record 33906641. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33906641
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References117
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23243584 | Targeting PD-1/PD-L1 interactions for cancer immunotherapy. | Oncoimmunology | 2012 | https://conductscience.org/library/papers/23243584 | PubMed |
| 2 | 15794662 | Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. | Biochemistry | 2005 | https://conductscience.org/library/papers/15794662 | PubMed |
| 3 | 20373055 | High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. | Med Oncol | 2011 | https://conductscience.org/library/papers/20373055 | PubMed |
| 4 | 32698317 | Monoclonal Antibodies in Cancer Therapy. | Antibodies (Basel) | 2020 | https://conductscience.org/library/papers/32698317 | PubMed |
| 5 | 32375257 | Kaempferol and Its Glycoside, Kaempferol 7-O-Rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32375257 | PubMed |
| 6 | 25524383 | Current advances in T-cell-based cancer immunotherapy. | Immunotherapy | 2014 | https://conductscience.org/library/papers/25524383 | PubMed |
| 7 | 30107136 | A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018). | Expert Opin Ther Pat | 2018 | https://conductscience.org/library/papers/30107136 | PubMed |
| 8 | 32185706 | Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. | Adv Exp Med Biol | 2020 | https://conductscience.org/library/papers/32185706 | PubMed |
| 9 | 28881701 | PD1 signal transduction pathways in T cells. | Oncotarget | 2017 | https://conductscience.org/library/papers/28881701 | PubMed |
| 10 | 26945088 | Genetic and Epigenetic Regulation of PD-1 Expression. | J Immunol | 2016 | https://conductscience.org/library/papers/26945088 | PubMed |
| 11 | 12407406 | Cancer immunoediting: from immunosurveillance to tumor escape. | Nat Immunol | 2002 | https://conductscience.org/library/papers/12407406 | PubMed |
| 12 | 29208386 | Cancer, checkpoint inhibitors, and confusion. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/29208386 | PubMed |
| 13 | 27269937 | Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27269937 | PubMed |
| 14 | 18173375 | PD-1 and its ligands in tolerance and immunity. | Annu Rev Immunol | 2008 | https://conductscience.org/library/papers/18173375 | PubMed |
| 15 | 30917623 | Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. | Molecules | 2019 | https://conductscience.org/library/papers/30917623 | PubMed |
| 16 | 32127660 | Trends in clinical development for PD-1/PD-L1 inhibitors. | Nat Rev Drug Discov | 2020 | https://conductscience.org/library/papers/32127660 | PubMed |
| 17 | 33224152 | Anticancer Effect of Salvia plebeia and Its Active Compound by Improving T-Cell Activity via Blockade of PD-1/PD-L1 Interaction in Humanized PD-1 Mouse Model. | Front Immunol | 2020 | https://conductscience.org/library/papers/33224152 | PubMed |
| 18 | 31151293 | Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles. | Molecules | 2019 | https://conductscience.org/library/papers/31151293 | PubMed |
| 19 | 30068796 | Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction. | Chem Pharm Bull (Tokyo) | 2018 | https://conductscience.org/library/papers/30068796 | PubMed |
| 20 | 19258005 | Development of a homogeneous immunoassay for the detection of angiotensin I in plasma using AlphaLISA acceptor beads technology. | Anal Biochem | 2009 | https://conductscience.org/library/papers/19258005 | PubMed |
Cited by46
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 80 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42797484 | Integrated Machine Learning and Molecular Simulation-Guided Discovery of Novel Small-Molecule PD-L1 Inhibitors. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42797484 | PubMed |
| 42741629 | Multiscale Explainable Machine Learning Reveals Descriptor-Invariant Molecular Determinants of Small-Molecule PD-1/PD-L1 Inhibition. | ACS Med Chem Lett | 2026 | https://conductscience.org/library/papers/42741629 | PubMed |
| 42649276 | A general strategy towards multicolour fluorogenic peptides for wash-free bioassays. | Nat Chem | 2026 | https://conductscience.org/library/papers/42649276 | PubMed |
| 42646619 | A Small Natural Molecule Targeting IL-23/IL-17 Axis Exerts Dual Effects on T-Cell Function and Breast Cancer Cell Migration. | Med Sci (Basel) | 2026 | https://conductscience.org/library/papers/42646619 | PubMed |
| 42388631 | Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance. | Front Oncol | 2026 | https://conductscience.org/library/papers/42388631 | PubMed |
| 42248963 | In silico screen identifies Pranidipine as a potential inhibitor of the PD-1/PD-L1 immune checkpoint. | Sci Rep | 2026 | https://conductscience.org/library/papers/42248963 | PubMed |
| 42018553 | In search of novel PD1 inhibitor from natural products by high-throughput virtual screening and molecular dynamics simulation. | PLoS One | 2026 | https://conductscience.org/library/papers/42018553 | PubMed |
| 41850740 | Intratumoral PD-1-directed IL-2 expression via oncolytic vaccinia virus elicits superior antitumor effects with enhanced safety. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/41850740 | PubMed |
| 41765960 | KCTD1 stabilizes c-Myc to upregulate PD-L1 and suppress anti-tumor immunity in hepatocellular carcinoma. | Cell Death Discov | 2026 | https://conductscience.org/library/papers/41765960 | PubMed |
| 41593769 | Paroxetine repurposing enhances antitumor immunity via SPOP-mediated PD-L1 ubiquitination and proteasomal degradation. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41593769 | PubMed |
| 41333481 | Mechanisms of immunotherapy in cutaneous squamous cell carcinoma in the tumor microenvironment. | Front Immunol | 2025 | https://conductscience.org/library/papers/41333481 | PubMed |
| 41051039 | Novel PD-L1 Small-Molecule Inhibitors Advancing Cancer Immunotherapy. | Anticancer Agents Med Chem | 2026 | https://conductscience.org/library/papers/41051039 | PubMed |
| 40944777 | Targeting tumor immune evasion: the role of PD-L1 siRNA in advancing cancer immunotherapy. | Med Oncol | 2025 | https://conductscience.org/library/papers/40944777 | PubMed |
| 40791660 | Targeted protein degradation with small molecules for cancer immunotherapy. | Asian J Pharm Sci | 2025 | https://conductscience.org/library/papers/40791660 | PubMed |
| 40106025 | Investigation the immunotherapeutic potential of miR-4477a targeting PD-1/PD-L1 in breast cancer cell line using a CD8+ co-culture model. | Mol Biol Rep | 2025 | https://conductscience.org/library/papers/40106025 | PubMed |
| 40075112 | Activin A affects colorectal cancer progression and immunomodulation in a stage dependent manner. | Sci Rep | 2025 | https://conductscience.org/library/papers/40075112 | PubMed |
| 40005217 | A Comparative Molecular Dynamics Study of Food-Derived Compounds as PD-L1 Inhibitors: Insights Across Six Flavonoid Subgroups. | Molecules | 2025 | https://conductscience.org/library/papers/40005217 | PubMed |
| 39696327 | Metabolizable alloy clusters assemble nanoinhibitor for enhanced radiotherapy of tumor by hypoxia alleviation and intracellular PD-L1 restraint. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/39696327 | PubMed |
| 39455819 | Sinulariapeptide F, a new peptide from culture broth of marine-derived fungus Simplicillium sp. SCSIO 41222. | J Antibiot (Tokyo) | 2025 | https://conductscience.org/library/papers/39455819 | PubMed |
| 39413175 | Small molecules from antibody pharmacophores (SMAbPs) as a hit identification workflow for immune checkpoints. | Sci Adv | 2024 | https://conductscience.org/library/papers/39413175 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| TRBV20OR9-2 | 6962 | PubTator's text mining | https://conductscience.org/library/genes/6962 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33906641
GET https://conductscience.org/api/papers/v1/33906641/references?page=2